CN116173099B - Application of Ertian oil in preparation of product for treating respiratory tract virus infection - Google Patents
Application of Ertian oil in preparation of product for treating respiratory tract virus infection Download PDFInfo
- Publication number
- CN116173099B CN116173099B CN202310418896.4A CN202310418896A CN116173099B CN 116173099 B CN116173099 B CN 116173099B CN 202310418896 A CN202310418896 A CN 202310418896A CN 116173099 B CN116173099 B CN 116173099B
- Authority
- CN
- China
- Prior art keywords
- oil
- product
- virus
- cytopathy
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides application of the diAN_SNer oil in preparing a product for treating respiratory tract virus infection, relates to the field of medicines, has obvious inhibition effect on influenza virus FM1 strain and human coronavirus HCOV-229E strain in-vitro culture A549 cytopathy, has inhibition effect on hep-2 cytopathy caused by respiratory tract syncytial virus in-vitro culture, and can be used for preparing the product for treating respiratory tract virus infection.
Description
Technical Field
The invention relates to the field of medicines, in particular to application of diurnal oil in preparing a product for treating respiratory tract virus infection.
Background
The second day oil is a wind-dispelling stimulant, and is commonly used for common cold, dizziness or heatstroke, and its main ingredients are menthol, peppermint oil and borneol.
For the two-day oil, literature: zhou Yanwen, jiang Weizhe, cai Guangming, etc. two-day oil is useful for treating common cold and safety study [ J ]. University of Guangxi Chinese medicine,2003, 6 (002): 1-3. Two-day oil is disclosed for alleviating early symptoms of common cold, such as headache, nasal obstruction, nasal discharge, sneeze, etc., but its use in the preparation of a product for treating respiratory viral infections is not disclosed, and it is pointed out that two-day oil is useful only for the early symptoms of nasopharyngeal catarrh of common cold, but for the late, severe, viral or bacterial-combined common cold, a targeted drug treatment should be used.
However, for key components in the two-day oil, such as peppermint oil, the prior art (e.g., schuhmacher A, reichling J, schnitzler P Virucidal effect of peppermint oil on the enveloped viruses herpes simplex virus type 1 and type 2 in vitro [ J ]. Phytomedicine,2003, 10 (6-7): 504-510.) also discloses that peppermint oil has an inhibitory effect on two subtypes of herpes simplex virus (HSV 21, HSV 22) and has no relevant description of peppermint oil inhibiting new coronaviruses and the like.
At present, other prior art also has no related research on the application of the two-day oil in preparing products for treating respiratory tract virus infection.
Aiming at the problem, the application field of the two-day oil is further expanded, and the research on the application of the two-day oil in preparing products for treating respiratory tract virus infection is necessary.
Disclosure of Invention
Aiming at the problems existing in the prior art, the invention provides the application of the diAN_SNer oil in preparing a product for treating respiratory tract virus infection.
The invention provides application of a two-day oil in preparation of a product for treating respiratory tract virus infection, wherein the concentration of the two-day oil in the product is less than or equal to 0.25mg/mL.
Further, the respiratory viruses include one or more of influenza virus, human coronavirus, and respiratory syncytial virus.
Preferably, the respiratory viruses include one or more of influenza virus FM1 strain, human coronavirus HCOV-229E strain and respiratory syncytial virus.
Further, the respiratory virus is a human coronavirus HCOV-229E strain.
Further, the concentration of the two-day oil in the product is 0.032-0.25mg/mL.
Preferably, the concentration of the two-day oil in the product is 0.0625-0.25mg/mL.
Further preferably, the concentration of the two-day oil in the product is 0.125-0.25mg/mL.
In some specific embodiments, the concentration of the two-day oil in the product is 0.0625-0.25mg/mL when the respiratory virus is influenza virus FM1 strain, 0.032-0.25mg/mL when the respiratory virus is human coronavirus HCOV-229E strain, and 0.125-0.25mg/mL (excluding 0.125 mg/mL) when the respiratory virus is respiratory syncytial virus.
Further, the product comprises a medicament.
Further, the components of the medicine comprise the common oil and pharmaceutically acceptable auxiliary materials.
Further, the dosage forms of the medicine comprise tablets, granules, capsules, dripping pills, gels, pastes and patches.
Further, the components of the two-day oil comprise menthol, peppermint oil and borneol.
The invention has the technical effects that:
the two-day oil has obvious inhibition effect on the in-vitro culture A549 cytopathy of the influenza virus FM1 strain and the human coronavirus HCOV-229E strain, and simultaneously has inhibition effect on the in-vitro culture hep-2 cytopathy caused by respiratory syncytial virus, and the comprehensive therapeutic index indicates that the two-day oil has more obvious antiviral effect.
Detailed Description
Other advantages and effects of the present invention will become apparent to those skilled in the art from the following disclosure, which describes the embodiments of the present invention with reference to specific examples. The invention may be practiced or carried out in other embodiments that depart from the specific details, and the details of the present description may be modified or varied from the spirit and scope of the present invention.
Before the embodiments of the invention are explained in further detail, it is to be understood that the invention is not limited in its scope to the particular embodiments described below; it is also to be understood that the terminology used in the examples of the invention is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the invention.
Where numerical ranges are provided in the examples, it is understood that unless otherwise stated herein, both endpoints of each numerical range and any number between the two endpoints are significant both in the numerical range. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
It should be noted that the raw materials used in the present invention are all common commercial products, and therefore the sources thereof are not particularly limited.
Example 1
1. Test materials
1.1 cell lines: human lung cancer cell A549, human laryngeal carcinoma epithelial cell hep-2 is purchased from Beijing North Innovative biological technology institute, passaged in this room and preserved in liquid nitrogen for later use.
1.2 viral strains: influenza A H1N1 virus (FM 1 strain), human coronavirus 229E (HCOV-229E), respiratory syncytial virus (RSV strain), purchased from the American type standard biological collection (ATCC). The room is passaged and stored in a refrigerator at the temperature of minus 80 ℃ for standby.
1.3 test drug
Is provided by Guangzhou white cloud mountain stars (pharmaceutical industry) stock. Day oil, sample lot number: SE220722a, sample properties: the liquid was clear in a reddish brown color.
Positive control drug: ribavirin granules, manufactured by Sichuan Baili pharmaceutical Co., ltd., batch number 200202. The mother solution of 5mg/mL is prepared by high-purity water before the test, and the mother solution is filtered and sterilized for later use.
1.4 test reagents
TABLE 1 test reagent case
1.5 test instrument
Table 2 test instrument conditions
2. Test method and results
2.1 culturing cells
The mixture was treated with 0.25% pancreatin in the conventional mannerA549 cells were digested and centrifuged at 1000rpm/min for 5min. Removing pancreatin, adding 10ml DMEM cell culture solution, blowing cells uniformly, inoculating into 96-well cell culture plate at 37deg.C with 5% CO, and 100 ul/well 2 After 24h culture in incubator, cell monolayer was grown for test.
The hep-2 cells were digested with 0.25% pancreatin according to the conventional method, centrifuged at 1000rpm/min for 5min. Removing pancreatin, adding 10ml DMEM cell culture solution, blowing cells uniformly, inoculating into 96-well cell culture plate at 37deg.C with 5% CO, and 100 ul/well 2 After 24h culture in incubator, cell monolayer was grown for test.
2.2 pharmaceutical preparation
Two day oil solution: adding 10 parts of two-day oil and 10 parts of tween-80, uniformly mixing by ultrasonic treatment, adding 180 parts of sterilized water, and dissolving by ultrasonic treatment (without sterilizing again). The cell culture solution 1960 μl and the two-day oil solution 40 μl are uniformly mixed before the test, and the mother solution is the two-day oil mother solution with the concentration of 1mg/ml.
Ribavirin granules: the mother solution of 5mg/mL is prepared by high-purity water before the test, and the mother solution is filtered and sterilized for later use.
The mother liquor concentration is used as the initial concentration in the drug test, and the cell maintenance solution is used for 2-fold dilution in the cytotoxicity test, and the total dilution is 8. The drug effect is tested at TC 0 At 8 dilution concentrations.
2.3 Toxicity test of two-day oil on in vitro culture A549, hep-2 cells
Taking the concentration of the mother solution as the initial concentration, diluting with the cell maintenance solution by 2 times, setting 8 dilutions altogether, adding into the A549 and hep-2 cell culture plates which grow into monolayers, and setting 3 compound wells for each dilution and normal cell control. Placing the culture plate at 37deg.C and 5% CO 2 Culturing in incubator, observing cytopathy condition under daily inverted microscope for 72 hr, and determining minimum dilution multiple (maximum nontoxic concentration TC) of cells without obvious lesion 0 ) And 50% cytotoxicity concentration (TC) was calculated according to Reed-Muench method 50 ）。
Cytopathy is judged according to a grade 6 standard:
-: the cells grow normally without lesions;
and (3) the following steps: cytopathic effect is less than 10% of the whole monolayer;
+: cytopathy accounts for less than about 25% of the whole monolayer;
++: cytopathy accounts for less than about 50% of the whole monolayer;
+++: cytopathy accounts for less than 75% of the whole monolayer;
++++: cytopathy accounts for about 75% or more of the whole monolayer.
TABLE 3 toxic effects of two day oil on in vitro culture A549 cells
Note that: cytopathic scoring: "+" =1, "+++" =2, "++", etc the number of the samples is =2, "+++", etc =4, 3 and scoring the multiple holes respectively.
Table 3 the results show that: maximum non-toxic concentration of the two-day oil (TC) 0 ) The dilution is that the mother solution is diluted by 1:4 times, the drug concentration is 0.25mg/ml, TC 50 The value was 0.335mg/ml.
TABLE 4 toxic effects of two day oil on in vitro culture of hep-2 cells
Note that: cytopathic scoring: "+" =1, "+++" =2, "++", etc the number of the samples is =2, "+++", etc =4, 3 scoring the multiple holes separately
Table 4 the results show that: maximum non-toxic concentration of the two-day oil (TC) 0 ) The dilution is that the mother solution is diluted by 1:4 times, the drug concentration is 0.25mg/ml, TC 50 The value was 0.335mg/ml.
2.4 Inhibition of two-day oil on in vitro culture A549 cytopathy caused by FM1 strain and HCOV-229E strain of influenza virus
Taking A549 cell culture plates growing into monolayers, pouring out the culture solution, and respectively inoculating 100TCID 50 H1N1 influenza virus (FM 1 strain), human coronavirus 229E (HCOV-229E) 100 μl/well, placing at 37deg.C, 5% CO 2 After adsorbing for 1h in an incubator, removing virus liquid, flushing the cell surface with cell maintenance liquid for 3 times, sequentially adding each liquid medicine with 7-8 dilutions below the maximum non-toxic concentration, 100 μl/hole, and simultaneously setting normal cell control, virus control and ribavirin Lin Duizhao. Placing at 37deg.C 5% CO 2 Culturing in incubator, observing cytopathy condition under inverted microscope every day, after 72h the virus control group cytopathy is the time of the++ to+++ is recorded the test results are recorded. 50% Inhibition Concentration (IC) calculated as Reed-Muench 50 ) And Therapeutic Index (TI), ti=tc 50 /IC 50 。
Cytopathy is judged according to a grade 6 standard:
-: the cells grow normally without lesions;
and (3) the following steps: cytopathic effect is less than 10% of the whole monolayer;
+: cytopathy accounts for less than about 25% of the whole monolayer;
++: cytopathy accounts for less than about 50% of the whole monolayer;
+++: cytopathy accounts for less than 75% of the whole monolayer;
++++: cytopathy accounts for about 75% or more of the whole monolayer.
TABLE 5 inhibition of respiratory viruses by two day oil on in vitro culture of A549 cells
Note that: cytopathic scoring: "+" =1, "+++" =2, "++", etc the number of the samples is =2, "+++", etc =4, 3 scoring the compound holes respectively;
IC50 units: (two days oil: mg/ml).
Table 5 the results show that: the two-day oil convection virus FM1 strain and the human coronavirus HCOV-229E strain have different degrees of inhibition effects on cytopathy, wherein the two-day oil convection virus FM1 strain and the human coronavirus HCOV-229E strain IC 50 0.045 mg/ml and 0.022 mg/ml, respectively, the therapeutic index TI is 7.89 and 16.14, respectively.
2.5 Inhibition of RSV-induced in vitro culture hep-2 cytopathy by two-day oil
Taking hep-2 cell culture plate growing into single layer, pouring out culture solution, respectively inoculating 100TCID 50 100. Mu.l/well of Respiratory Syncytial Virus (RSV), placed at 37℃in 5% CO 2 After adsorbing for 1h in an incubator, removing virus liquid, flushing the cell surface with cell maintenance liquid for 3 times, sequentially adding 7-8 dilutions of each liquid medicine below the maximum non-toxic concentration, 100 μl/hole, and simultaneously setting normal cell control, virus control and ribavirin (RSV positive control medicine) control. Placing at 37deg.C 5% CO 2 Culturing in incubator, observing cytopathy condition under inverted microscope every day, after 72h the virus control group cytopathy is the time of the++ to+++ is recorded the test results are recorded. 50% Inhibition Concentration (IC) calculated as Reed-Muench 50 ) And Therapeutic Index (TI), ti=tc 50 /IC 50 。
Cytopathy is judged according to a grade 6 standard:
-: the cells grow normally without lesions;
and (3) the following steps: cytopathic effect is less than 10% of the whole monolayer;
+: cytopathy accounts for less than about 25% of the whole monolayer;
++: cytopathy accounts for less than about 50% of the whole monolayer;
+++: cytopathy accounts for less than 75% of the whole monolayer;
++++: cytopathy accounts for about 75% or more of the whole monolayer.
TABLE 6 inhibition of respiratory viruses by two day oils on hep-2 cells cultured in vitro
Note that: cytopathic scoring: "+" =1, "+++" =2, "++", etc the number of the samples is =2, "+++", etc =4, 3 scoring the compound holes respectively; IC50 units: (two days oil: mg/ml).
Table 6 the results show that: two-day oil has various degrees of inhibition on Respiratory Syncytial Virus (RSV) cytopathy, wherein the two-day oil has IC (integrated circuit) on RSV 50 Is 0.178 mg-ml, therapeutic index TI was 2.0.
Comprehensively considering the values of Therapeutic Indexes (TI), the two-day oil has obvious inhibition effect on the cytopathy of the influenza virus FM1 strain and the human coronavirus HCOV-229E strain cultured in vitro A549, and the Therapeutic Indexes (TI) are respectively 7.89 and 16.14; the two-day oil has an inhibitory effect on the in vitro culture of hep-2 cytopathy caused by respiratory syncytial virus, and the Therapeutic Index (TI) is 2.0. The comprehensive result shows that the two-day oil has better antiviral effect.
3. Conclusion(s)
The two-day oil has obvious inhibition effect on the in-vitro culture A549 cytopathy of the influenza virus FM1 strain and the human coronavirus HCOV-229E strain, and simultaneously has inhibition effect on the in-vitro culture hep-2 cytopathy caused by the respiratory syncytial virus, and the comprehensive therapeutic index indicates that the two-day oil has obvious antiviral effect.
Finally, it should be noted that the above description is only for illustrating the technical solution of the present invention, and not for limiting the scope of the present invention, and that the simple modification and equivalent substitution of the technical solution of the present invention can be made by those skilled in the art without departing from the spirit and scope of the technical solution of the present invention.
Claims (7)
1. The application of the diurnal oil in preparing a product for treating respiratory tract virus infection is characterized in that: the concentration of the two-day oil in the product is less than or equal to 0.25mg/mL;
the respiratory virus is human coronavirus HCOV-229E strain.
2. The use according to claim 1, characterized in that: the concentration of the two-day oil in the product is 0.032-0.25mg/mL.
3. The use according to claim 1, characterized in that: the concentration of the two-day oil in the product is 0.0625-0.25mg/mL.
4. The use according to claim 1, characterized in that: the concentration of the two-day oil in the product is 0.125-0.25mg/mL.
5. The use according to claim 1, characterized in that: the product comprises a medicament.
6. The use according to claim 5, characterized in that: the components of the medicine comprise the common oil and pharmaceutically acceptable auxiliary materials.
7. The use according to claim 5, characterized in that: the dosage forms of the medicine comprise tablets, granules, capsules, dripping pills, gels, pastes and patches.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310418896.4A CN116173099B (en) | 2023-04-19 | 2023-04-19 | Application of Ertian oil in preparation of product for treating respiratory tract virus infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310418896.4A CN116173099B (en) | 2023-04-19 | 2023-04-19 | Application of Ertian oil in preparation of product for treating respiratory tract virus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116173099A CN116173099A (en) | 2023-05-30 |
| CN116173099B true CN116173099B (en) | 2023-09-08 |
Family
ID=86434744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310418896.4A Active CN116173099B (en) | 2023-04-19 | 2023-04-19 | Application of Ertian oil in preparation of product for treating respiratory tract virus infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116173099B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104161902A (en) * | 2014-08-25 | 2014-11-26 | 漳州片仔癀药业股份有限公司 | Pharmaceutical composition and novel use of preparation of pharmaceutical composition in preparation of anti-influenza drug |
| CN113209203A (en) * | 2021-05-18 | 2021-08-06 | 江西中医药大学 | Antiviral compound essential oil and application thereof |
| CN113975314A (en) * | 2021-10-27 | 2022-01-28 | 广东罗浮山国药股份有限公司 | Application of oil of dahurian rhododendron leaf in preparing medicine for preventing or treating respiratory infectious diseases |
| CN115372535A (en) * | 2022-08-09 | 2022-11-22 | 广州白云山星群(药业)股份有限公司 | Thin-layer chromatography detection method for two-day oil |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014062892A1 (en) * | 2012-10-19 | 2014-04-24 | Flutrends International, Llc | Anti-viral compositions |
-
2023
- 2023-04-19 CN CN202310418896.4A patent/CN116173099B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104161902A (en) * | 2014-08-25 | 2014-11-26 | 漳州片仔癀药业股份有限公司 | Pharmaceutical composition and novel use of preparation of pharmaceutical composition in preparation of anti-influenza drug |
| CN113209203A (en) * | 2021-05-18 | 2021-08-06 | 江西中医药大学 | Antiviral compound essential oil and application thereof |
| CN113975314A (en) * | 2021-10-27 | 2022-01-28 | 广东罗浮山国药股份有限公司 | Application of oil of dahurian rhododendron leaf in preparing medicine for preventing or treating respiratory infectious diseases |
| CN115372535A (en) * | 2022-08-09 | 2022-11-22 | 广州白云山星群(药业)股份有限公司 | Thin-layer chromatography detection method for two-day oil |
Non-Patent Citations (1)
| Title |
|---|
| 周燕文等.二天油治疗伤风感冒有效性及安全性研究.广西中医学院学报.2003,6(02),第1-3页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116173099A (en) | 2023-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tolo et al. | Anti-viral activity of the extracts of a Kenyan medicinal plant Carissa edulis against herpes simplex virus | |
| WO2021213058A1 (en) | Application of traditional chinese medicine composition in preparation of drugs for treating or preventing infection with coronaviruses | |
| US20070123566A1 (en) | Isoflavone derivatives of tectoridin, the preparation thereof and the anti-virus medicines containing the same as an effective constituents | |
| CN105418410B (en) | Emodin derivates and its application in the medicine of AntiHIV1 RT activity 1 is prepared | |
| WO2023273558A1 (en) | Use of exocarpium citri grandis productive cough extract in preparation of drug for inhibiting human coronavirus infection | |
| CN113440563A (en) | Compound houttuynia cordata spray and preparation method and application thereof | |
| CN116173099B (en) | Application of Ertian oil in preparation of product for treating respiratory tract virus infection | |
| CN104382968B (en) | Extraction method of andrographolide, andrographolide pharmaceutical composition and application | |
| CN107737201B (en) | Application of radix tetrastigme extract in resisting virus | |
| CN113855654A (en) | A composition for preventing and treating coronavirus infection | |
| US20230173006A1 (en) | Application of traditional chinese medicine composition to preparation of medicine for treating or preventing coronavirus infection | |
| US20030054047A1 (en) | Pharmaceutical composition for the treatment of viral infection | |
| WO2024001265A1 (en) | Use of ophiopogonin d in preparing anti-rotavirus medicament | |
| Odimegwu et al. | Anti-respiratory syncytial virus activities of leaf extracts of Alchornea cordifolia and Alchornea floribunda | |
| CN116077528A (en) | Application of gallic acid carbon dots in resisting pseudorabies virus | |
| CN116634883A (en) | Method for producing pharmaceutical preparations | |
| US9913861B2 (en) | Anti-virally effective pharmaceutical composition | |
| WO2021164401A1 (en) | Use of traditional chinese medicine composition in preparation of drugs for treating or preventing coronavirus infection | |
| CN106552148B (en) | Pharmaceutical composition for resisting H7N9 avian influenza virus | |
| Sun et al. | In vitro antiviral effect of fructopyrano-(1→4)-glucopyranose from Radix isatidis on infuenza virus A | |
| CN112022867A (en) | Application of geraniin in preparing medicine for resisting novel coronary virus | |
| CN113230253B (en) | Antiviral composition and application thereof in preparation of medicine for preventing and/or treating herpes virus | |
| WO2006053487A1 (en) | The use of vegetable anthraquinone derivatives and vegetable polysaccharides for treating human immunodeficiency virus (hiv) | |
| CN115364129B (en) | Application of herba Pileae Scriptae or its extract, and preparation for clearing heat and relieving inflammation in preparation of anti-coronavirus medicine and preparation method thereof | |
| CN113440562B (en) | Application of compound houttuynia cordata mixture in preparation of medicine for preventing or treating coronavirus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40088390 Country of ref document: HK |